Gan & Lee Pharmaceuticals vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Gan & Lee Pharmaceuticals Co Ltd (603087.CG)

Q3 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

September 202627 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Latest27 Jul – 8 Oct 2026

▲4

Gan & Lee's obesity drug goes global as pipeline and profits advance

Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.